Expression of hepatocyte growth factor and c-MET in skull base chordoma

Cancer

Volumn 112, Issue 1, 2008, Pages 104-110

  Naka, Takahiko ^a,d   Kuester, Doerthe ^a   Boltze, Carsten ^a   Scheil Bertram, Stefanie ^b   Samii, Amir ^c   Herold, Christian ^c   Ostertag, Helmut ^c   Krueger, Sabine ^a   Roessner, Albert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c NORDSTADT HOSPITAL   (Germany)

^d KYUSHU ROSAI HOSPITAL   (Japan)

Author keywords

c MET; Chordoma; Epithelial differentiation; Hepatocyte growth factor; Invasion; Prognosis; Proliferation; Proteinase

Indexed keywords

CYTOKERATIN; PROTEINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CHORDOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SKULL BASE TUMOR;

ADOLESCENT; ADULT; AGED; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; CHORDOMA; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; SKULL BASE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 37449007862     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23141     Document Type: Article

References (51)

1. Gherardi E, Sharpe M, Lane K, Sirulnik A, Stoker M. Hepatocyte growth factor/scatter factor (HGF/SF), the c-Met receptor and the behavior of epithelial cells. Symp Soc Exp Biol. 1993;47:163-181.
2. Rubin J, Bottaro D, Aaronson S. Hepatocyte growth factor/scatter factor and its receptor, the c-Met proto-oncogene product. Biochim Biophys Acta. 1993;1155:357-371.
3. Weidner K, Hartmann G, Naldini L, et al. Molecular characteristics of HGF-SF and its role in cell motility and invasion. EXS. 1993;65:311-328.
4. Zarnegar R. Regulation of HGF and HGFR gene expression. EXS. 1993;74:33-49.
5. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell motility. Nature. 1987;327:239-242.
6. Bussolino F, Di Renzo MF, Ziehe M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119:629-641.
7. Michalopoulos GK. Liver regeneration: molecular mechanisms of growth control. FASEB J. 1990;4:176-187.
8. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440-443.
9. Matsumoto K, Tajima H, Nakamura T. Hepatocyte growth factor is a potent stimulator of human melanocyte DNA synthesis and growth. Biochem Biophys Res Commun. 1991;176:45-51.
10. Rubin JS, Chan AM, Bottaro DP, et al. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci USA. 1991;88:415-419.
11. Kan M, Zhang G, Zarnegar R, et al. Hepatocyte growth factor, hepatopietin-A stimulates the growth of rat kidney proximal tubules epithelial cell (rpte), rat nonparechymal liver cells, human melanoma cells and mouse keratinocytes, and stimulates anchorage independent growth of SV40-transfo. Biochem Biophys Res Commun. 1991;174:331-337.
12. Montesano R, Matsumono K, Nakamura T, Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell. 1991;67:901-908.
13. Tsarfaty I, Resau JH, Rulong SL, Keydar I, Faletto DL, Vande Woude GF. The met proto-oncogene receptor and lumen formation. Science. 1992;257:1258-1261.
14. Gherardi E, Gray J, Stoker J, Perryman M, Furlong R. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc Natl Acad Sci U S A. 1989;86:5844-5848.
15. Comoglio P. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. EXS. 1993;65:130-165.
16. Nakamura S, Gohda E, Matsunaga T, Yamamoto I, Minowada J. Production of hepatocyte growth factor by human haematopoietic cell lines. Cytokine. 1994;6:285-294.
17. Di Renzo MF, Narsimhan RP, Oliviero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissue. Oncogene. 1991;6:1997-2003.
18. Prat M, Narsimham BP, Crepaldi T, Nicotra MR, Natali PG, Comoglio PM. The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer. 1991;49:323-328.
19. Sonnenberg E, Meyer D, Weider K, Birchmeier C. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol. 1993;123:223-235.
20. Park M, Dean M, Cooper C, Schmidt M, O'Brian S, Blair D. Mechanism of met oncogene activation. Cell. 1986;45:895-904.
21. Cooper C, Park M, Blair D, Tainsky M, Huebner K, Croce C. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311:29-33.
22. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol. 1992;12:5152-5158.
23. Jin L, Fuchs A, Schnitt SJ, et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer. 1997;79:749-760.
24. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent amplification of the c-met gene in scirrhous-type stomach cancer. Biochem Biophys Res Commun. 1992;189:227-232.
25. Pisters L, Troncoso P, Zhau H, Li W, Eschenbach A, Chung L. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol. 1995;154:293-298.
26. Grigioni W, Fiorentino M, D'Errico A, Ponzetto A, Crepaldi T, Prat M. Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. Hepatology. 1995;21:1543-1546.
27. Oda Y, Sakamoto A, Saito T, Kinukawa N, Iwamoto Y, Tsuneyoshi M. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol. 2000;31:185-192.
28. Ferracini R, Di Renzo MF, Scotlandi K, et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either paracrine or an autocrine circuit. Oncogene. 1995;10:739-749.
29. Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande Woude GE Met expression and sarcoma tumorigenicity. Cancer Res. 1993;53:5355-5360.
30. Scotlandi K, Baldini N, Oliviero M, et al. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol. 1996;149:1209-1219.
31. Ruco LP, Ranalli T, Marzullo A, et al. Expression of Met protein in thyroid tumours. J Pathol. 1996;180:266-270.
32. Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol. 1998;29:175-180.
33. Nakapoulou L, Gakiopoulou H, Keramopoulos A, et al. c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology. 2000;36:313-325.
34. Aishima SI, Taguchi KI, Sugimachi K, et al. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology. 2002;40:269-278.
35. Furukawa T, Duguid WP, Kobari M, Matsuno S, Tsao MS. Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol. 1995;147:889-895.
36. Naka T, Iwamoto Y, Shinohara N, Ushijima M, Chuman H, Tsuneyoshi M. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol. 1997;10:832-838.
37. Weinberger PM, Yu Z, Kowalski D, et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chrodoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg. 2005;131:707-711.
38. O'Connell JX, Renard LG, Liebsch NJ, Efird JT, Munzerider JE, Rosenberg A. Base of skull chordoma: a correlative study of histologic and clinical features of 62 cases. Cancer. 1994;74:2261-2267.
39. Volpe R, Mazabraud A. A clinicopathologic review of 25 cases of chordoma: a pleomorphic and metastasizing neoplasm. Am J Surg Pathol. 1983;7:161-170.
40. Bergh P, Kindblom L, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom J. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000;88:2122-2134.
41. Naka T, Boltze C, Kuester D, et al. Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B and urokinase plasminogen activator in non-skull base chordoma. Am J Clin Pathol. 2004;122:926-930.
42. Naka T, Boltze C, Samii S, et al. Skull base and non-skull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer. 2003;98:1934-1941.
43. Naka T, Boltze C, Kuester D, et al. Intralesional fibrous septum in chordoma: a clinicopathologic and immunohistochemical analysis in 122 lesions. Am J Clin Pathol. 2005;124:288-294.
44. Kumaki F, Matsui K, Kawai T, et al. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol. 2001;159:2125-2135.
45. Naka T, Kuester D, Boltze C, et al. Expression of matrix metalloproteinases-1, -2, -9, tissue inhibitors of matrix metalloproteinases-1, -2, cathepsin B, urokinase plasminogen activator and plasminogen activator inhibitor-1 in skull base chordoma. Hum Pathol. In press.
46. Naka T, Boltze C, Kuester D, et al. Alterations of G1-S checkpoint in chordoma: prognostic impact of p53 overexpression. Cancer. 2005;104:1255-1263.
47. Belfiore A, Gangemi P, Costantino A, et al. Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab. 2006;82:2322-2328.
48. Scheil S, Bruederlein S, Liehr T, et al. Genome wide analysis of 16 chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosom Cancer. 2001;32:203-211.
49. Brandal P, Bjerkehagen B, Danielsen H, Heim S. Chromosome 7 abnormalities are common in chordomas. Cancer Genet Cytogenet. 2005;160:15-21.
50. Sawyer JR, Husain M, Al-Mefty O. Identification of isochromosome 1q as a recurring chromosome aberration in skull base chordomas: a new marker for aggressive tumors? Neurosurg Focus. 2001;10:1-6.
51. Naka T, Iwamoto Y, Shinohara N, Chuman H, Fukui M, Tsuneyoshi M. Cytokeratin subtyping in chordomas and fetal notochord: an immunohistochemical analysis of aberrant expression. Mod Pathol. 1997;10:545-551.